EMA
approval
· 2012-05-25
European Medicines Agency recommends first-in-class medicine for treatment of cystic fibrosis
Summary
EMA recommends a first-in-class medicine for treating cystic fibrosis, indicating a pivotal recommendation toward approval for a new mechanism of action in CF.
Upgrade for the full analysis, importance score, and drug timeline.